DDW’s Megan Thomas takes a wide-angle look at the sector and speaks to experts and thought leaders about their predictions for therapeutic antibodies in 2025. Clinical advancements Marcelo Freire, Vice President of Global Medical Affairs, Therapeutic Area Head of Gastroenterology at Takeda, comments on monoclonal antibodies (mAbs) from a gastro… Read More
Heidelberg Pharma is advancing into Cohort 7 in a Phase I/IIa dose escalation study with lead ATAC candidate HDP-101 for the treatment of relapsed or refractory multiple myeloma. Heidelberg uses the compound Amanitin from the green death cap mushroom in cancer therapy. The biological mechanism of action of the toxin… Read More
Antibody drug conjugates (ADCs) are among the hottest properties in pharma, powerful anticancer drugs that target tumours and deliver a lethal payload that destroys them, while leaving healthy tissues untouched. But there’s much more to come from this technology. DDW’s Megan Thomas explores the topic and speaks with experts… Read More
